表紙
企業レポート

製薬会社の業績一覧:2010年

Pharmaceutical Companies Performance Tables 2010

発行 Espicom Business Intelligence 商品コード 143307
出版日 ページ情報 英文 438 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
製薬会社の業績一覧:2010年 Pharmaceutical Companies Performance Tables 2010
出版日: 2011年01月05日 ページ情報: 英文 438 Pages
概要

当レポートでは、製薬会社162社のバランスシート、損益計算書、キャッシュフローから過去5年間の業績をまとめ、概略以下の構成でお届けいたします。

  • イントロダクション
  • 医薬品売上
  • 収益
  • 純利益
  • 粗利益
  • 基本利益
  • 営業利益
  • 営業利益生産性
  • 純利益生産性
  • キャッシュフロー
  • 研究開発費
  • SG&A経費
  • 設備投資
  • 負債総額
  • 長期負債
  • 資産
  • 資産総額
  • 有形資産
  • 無形・その他の資産
  • 従業員あたりの資産
  • 従業員
  • コスト総額
  • 流動負債
  • 販売コスト
  • 生産性
  • 株式
  • 投資率
  • 流動比率

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 4068

Abstract

META Description

In today' s challenging market, business planners and commercial management must ask themselves some key questions, such as

  • Who are the winners and losers in terms of revenue growth?
  • Which companies have succeeded in maintaining or growing profits?
  • Overall R&D investment from the top 10 companies fell between 2008 and 2009 by US$421 million from US$57.54 billion to US$57.12 billion - yet some companies maintained or expanded R&D spend. Who were they?
  • Who are the fastest growers? 10 companies with joint 2005 sales of US$2.55 billion posted sales of $US13.06 billion in 2009. Who were they?
  • Which companies are cash rich or cash poor?

Pharmaceutical Company Performance Tables The answers to thousands of key questions are in the new 2010 edition

This essential fully-updated business reference report compares and contrasts the performance and fortunes of leading pharmaceutical companies and places them in easy-to-read tables. Importantly, in addition to rankings, the new edition of the report includes the individual results for 162 companies and up to five years of key data from the balance sheet, income statement and cash flow.

Key Facts & Benefits of this report:

  • Full 2009 year-end figures
  • Contains a wide range of detailed performance rankings for more than 160 leading pharmaceutical companies
  • Includes individual company results
  • Provides up to five years of trend data
  • Available in print or pdf with web access included free of charge!

Trends affecting the global industry

The challenging economic environment continues to affect health spending in many countries which has impacted the pharmaceutical industry' s commercial performance. Issues which are affecting companies' performance, include

The number of blockbuster drugs which have lost patent protection, and the number is set to rise over the coming years, have not been replaced by new products offering significant therapeutic advances

Those products which have been launched - increasingly in the biological area - have attracted criticism and objection from health payers due to their high cost

Many companies continue to post rising revenues and increasing profits, although for many it is against a background of cost cutting

Mergers and acquisitions, and especially technology/product acquisition, have taken an increasing role in market entry/expansion plans

Generic competition continues to erode the profits of off-patent products, although spending constraints and rising competition are creating pressure in the generic sector. Pharmaceutical Companies Performance Tables A unique opportunity to assess companies' financial and operating performances.

Use it for

  • Competitor analysis
  • Acquisition targeting
  • Partnering and licensing background
  • PR and Marketing
  • Performance benchmarking

Just some of the 162 companies in the 2010 edition Abbott Laboratories

  • Abraxis BioScience
  • Ajinomoto
  • Alcon Laboratories
  • Allergan
  • Amgen
  • Amylin Pharmaceuticals
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • BTG International
  • Celgene
  • Chugai
  • CSL Limited
  • Cubist Pharmaceuticals
  • Cytokinetics
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Dendreon
  • Dr Reddy' s Labs
  • Egis
  • Eisai
  • Elan
  • Eli Lilly
  • Endo Pharmaceuticals
  • Enzon Pharmaceuticals
  • Eurand
  • Forest Laboratories
  • Gedeon Richter
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Hospira
  • Human Genome Sciences
  • ImmunoGen
  • Incyte
  • Inspire Pharmaceuticals
  • Ipsen
  • Isis Pharmaceuticals
  • Johnson & Johnson
  • KRKA
  • Kyowa Kirin
  • Lundbeck
  • Mannkind
  • Merck & Co
  • Merck KGaA
  • Mitsubishi Tanabe Pharma
  • Mylan Laboratories
  • Nipro
  • Novartis
  • Novo Nordisk
  • NPS Pharmaceuticals
  • Nycomed
  • Ono Pharmaceuticals
  • Orion
  • OSI Pharmaceuticals
  • Otsuka
  • Pfizer
  • Procter & Gamble
  • Ranbaxy
  • Recordati
  • Regeneron Pharmaceuticals
  • Roche
  • sanofi-aventis
  • Sawai
  • Shionogi
  • Shire Pharmaceuticals
  • Stada Arzneimittel
  • Takeda
  • Teva Pharmaceutical Industries
  • Theravance
  • UCB
  • Vertex Pharmaceuticals
  • XOMA
  • ZymoGenetics

Extensive Contents

Key Financial Indicators include:

  • Pharmaceutical Sales
  • Total Revenues
  • Cost of Sales
  • Operating Income
  • Net Income
  • Earnings per Share
  • R&D Expenditure
  • Capital Expenditure
  • Return on Capital Employed
  • Total Assets
  • Cash in Hand
  • Employees
  • Companies are also ranked by:
  • Productivity
  • Profitability
  • Research Rates
  • Investment Rates
  • Performance Indicators:
  • (Using Pharmaceutical Sales as an example)
  • Companies by Pharmaceutical Sales 2005-2009 (US$m)
  • Companies by Yearly Change (Local Currency)
  • Companies by Five-Year Change (Local Currency)
  • Five-Year Movement of Pharmaceutical Sales
  • (2000 constant US$ Exchange Rates)
  • Five-Year Change in Pharmaceutical Sales
  • (Index Numbers)

Table of Contents

Part 1

INTRODUCTION

Pharmaceutical Sales

  • Absolute Pharma Revenues (US$ millions YER)
  • Absolute Pharma Revenues (US$ millions CER)
  • 1 Year Percentage Change in Pharma Revenue (Local Currencies)
  • 1 Year Absolute Change in Pharma Revenue (US$ millions CER)
  • 5 Year Absolute Change in Pharma Revenue (US$ millions CER)
  • 5 Year Percentage Change in Pharma Revenue (Local Currencies)
  • Pharmaceutical Revenues by Company Location 2005-2009 - Japan, Asia & Rest of the World
  • Pharmaceutical Revenues by Company Location 2005-2009 - Europe
  • Pharmaceutical Revenues by Company Location 2005-2009 - United States
  • Pharmaceutical Revenues by Company Location 2005-2009 - Regional Comparisons

Revenues

  • Absolute Consolidated Revenue (US$ millions YER)
  • Absolute Consolidated Revenue (US$ millions CER)
  • 1 Year Percentage Change in Consolidated Revenue (Local Currencies)
  • 5 Year Percentage Change in Consolidated Revenue (Local Currencies)
  • 5 Year Absolute Change in Consolidated Revenue (US$ millions CER)
  • 1 Year Absolute Change in Consolidated Revenue (US$ millions CER)

Net Profits

  • Absolute Net Profits (US$ millions YER)
  • Absolute Net Profits (US$ millions CER)
  • Absolute Net Profitability %

Gross Profits

  • Absolute Gross Profits (US$ millions YER)
  • Absolute Gross Profits (US$ millions CER)
  • Underlying Profits
  • Absolute Underlying Profits (US$ millions YER)
  • Absolute Underlying Profits (US$ millions CER)
  • Absolute Underlying Profitability %

Operating Profits

  • Absolute Operating Profits (US$ millions YER)
  • Absolute Operating Profits (US$ millions CER)
  • Absolute Operating Profitability %

Operating Profit Productivity

  • Absolute Operating Profit Productivity (US$ millions YER)
  • Absolute Operating Profit Productivity (US$ millions CER)
  • 1 Year Absolute Change in Operating Profit Productivity (US$ millions CER)
  • 5 Year Absolute Change in Operating Profit Productivity (US$ millions CER)

Net Profit Productivity

  • Absolute Net Profit Productivity (US$ millions YER)
  • Absolute Net Profit Productivity (US$ millions CER)
  • 1 Year Absolute Change in Net Profit Productivity (US$ millions CER)
  • 5 Year Absolute Change in Net Profit Productivity (US$ millions CER)

Cash Flows

  • Absolute Net Cash Flows (US$ millions YER)
  • Absolute Net Cash Flows (US$ millions CER)
  • Absolute Operating Cash Flows (US$ millions YER)
  • Absolute Operating Cash Flows (US$ millions CER)
  • 5 Year Absolute Change in Operating Cash Flows (US$ millions CER)
  • 1 Year Absolute Change in Operating Cash Flows (US$ millions CER)
  • Absolute Financing Cash Flows (US$ millions YER)
  • Absolute Financing Cash Flows (US$ millions CER)
  • Absolute Investing Cash Flows (US$ millions YER)
  • Absolute Investing Cash Flows (US$ millions CER)
  • Absolute Cash in Hand (US$ millions YER)
  • Absolute Cash in Hand (US$ millions CER)
  • 5 Year Absolute Change in Cash in Hand (US$ millions CER)
  • 1 Year Absolute Change in Cash in Hand (US$ millions CER)
  • 5 Year Percentage Change in Cash in Hand (Local Currencies)
  • Percentage Change in Cash in Hand (Local Currencies)
  • Summation of Cash in Hand (US$ millions CER)
  • Percentage Liquidity against Total Assets
  • Percentage Liquidity against Consolidated Revenue

R&D Expenditure

  • Absolute R&D Expenditure (US$ millions YER)
  • Absolute R&D Expenditure (US$ millions CER)
  • 1 Year Absolute Change in R&D Expenditure (US$ millions CER)
  • 5 Year Absolute Change in R&D Expenditure (US$ millions CER)
  • 5 Year Percentage Change in R&D Expenditure (Local Currencies)
  • 1 Year Percentage Change in R&D Expenditure (Local Currencies)
  • Absolute Research Rate

SG&A Expenses

  • Absolute SG&A Expenses (US$ millions YER)
  • Absolute SG&A Expenses (US$ millions CER)
  • 1 Year Absolute Change in SG&A Expenses (US$ millions CER)
  • 5 Year Percentage Change in SG&A Expenses (Local Currencies)
  • 1 Year Percentage Change in SG&A Expenses (Local Currencies)
  • Absolute SG&A Rate

Capital Expenditure

  • Absolute Capital Expenditure (US$ millions YER)
  • Absolute Capital Expenditure (US$ millions CER)
  • 1 Year Absolute Change in Capital Expenditure (US$ millions CER)
  • 5 Year Absolute Change in Capital Expenditure (US$ millions CER)
  • 5 Year Percentage Change in Capital Expenditure (Local Currencies, Million)
  • 1 Year Percentage Change in Capital Expenditure (Local Currencies, Million)
  • Summation of Capital Expenditures (US$ millions CER)

Total Liabilities

  • Absolute Long Term Liabilities (US$ millions YER)
  • Absolute Long Term Liabilities (US$ millions CER)
  • 1 Year Absolute Change in Total Liabilities (US$ millions CER)
  • 5 Year Absolute Change in Total Liabilities (US$ millions CER)
  • 1 Year Percentage Change in Total Liabilities (Local Currencies)
  • 5 Year Percentage Change in Total Liabilities (Local Currencies)

Long Term Liabilities

  • Absolute Long Term Liabilities (US$ millions YER)
  • Absolute Long Term Liabilities (US$ millions CER)
  • 1 Year Absolute Change in Long Term Liabilities (US$ millions CER)
  • 5 Year Absolute Change in Long Term Liabilities (US$ millions CER)
  • 1 Year Percentage Change in Long Term Liabilities (Local Currencies)
  • 5 Year Percentage Change in Long Term Liabilities (Local Currencies)

Assets

  • Absolute Current Assets (US$ millions YER)
  • Absolute Current Assets (US$ millions CER)
  • 1 Year Absolute Change in Current Assets (US$ millions CER)
  • 5 Year Absolute Change in Current Assets (US$ millions CER)
  • 5 Year Percentage Change in Current Assets (Local Currencies)
  • 1 Year Percentage Change in Current Assets (Local Currencies)

Total Assets

  • Absolute Total Assets (US$ millions YER)
  • Absolute Total Assets (US$ millions CER)
  • 5 Year Absolute Change in Total Assets (US$ millions CER)
  • 1 Year Absolute Change in Total Assets (US$ millions CER)
  • 5 Year Percentage Change in Total Assets (Local Currencies)
  • 1 Year Percentage Change in Total Assets (Local Currencies)

Tangi ble Assets

  • Absolute Tangible Assets (US$ millions YER)
  • Absolute Tangible Assets (US$ millions CER)
  • 5 Year Absolute Change in Tangible Assets (US$ millions CER)
  • 1 Year Absolute Change in Tangible Assets (US$ millions CER)
  • Percentage Change in Tangible Assets (Local Currencies)
  • 5 Year Percentage Change in Tangible Assets (Local Currencies)

Intangible and Other Assets

  • Absolute Intangible and Other Assets (US$ millions YER)
  • Absolute Intangible and Other Assets (US$ millions CER)
  • 5 Year Absolute Change in Intangible and Other Assets (US$ millions CER)
  • 5 Year Absolute Change in Intangible and Other Assets (US$ millions CER)
  • 1 Year Percentage Change in Intangible and Other Assets (Local Currencies)
  • 5 Year Percentage Change in Intangible and Other Assets (Local Currencies)

Assets per Employee

  • Absolute Total Assets per Employee (US$ millions YER)
  • Absolute Total Assets per Employee (US$ millions CER)
  • 1 Year Absolute Change in Total Assets per Employee (US$ millions CER)
  • 5 Year Absolute Change in Total Assets per Employee (US$ millions CER)
  • 1 Year Percentage Change in Total Assets per Employee (Local Currencies)
  • 5 Year Percentage Change in Total Assets per Employee (Local Currencies)

Employees

  • Absolute Employees
  • 5 Year Absolute Change in Employees
  • 1 Year Absolute Change in Employees
  • 5 Year Percentage Change in Employees
  • 1 Year Percentage Change in Employees

Total Costs

  • Absolute Total Costs (US$ millions YER)
  • Absolute Total Costs (US$ millions CER)
  • 5 Year Absolute Change in Total Costs (US$ millions CER)
  • 1 Year Absolute Change in Total Costs (US$ millions CER)
  • 5 Year Percentage Change in Total Costs (US$ millions LC)
  • 1 Year Percentage Change in Total Costs (Local Currency)

Current Liabilities

  • Absolute Current Liabilities (US$ millions YER)
  • Absolute Current Liabilities (US$ millions CER)
  • 5 Year Absolute Change in Current Liabilities (US$ millions CER)
  • 1 Year Absolute Change in Current Liabilities (US$ millions CER)
  • 5 Year Percentage Change in Current Liabilities (Local Currencies)
  • 1 Year Percentage Change in Current Liabilities (Local Currencies)

Cost of Sales

  • Absolute Cost of Sales (US$ millions YER)
  • Absolute Cost of Sales (US$ millions CER)
  • 5 Year Absolute Change in Cost of Sales (US$ millions CER)
  • 1 Year Absolute Change in Cost of Sales (US$ millions CER)
  • 5 Year Percentage Change in Cost of Sales (Local Currencies)
  • 1 Year Percentage Change in Cost of Sales (Local Currencies)

Productivity

  • Absolute Revenue Productivity (US$ YER)
  • Absolute Revenue Productivity (US$ CER)
  • 1 Year Absolute Change in Revenue Productivity (US$ CER)
  • 5 Year Absolute Change in Revenue Productivity (US$ CER)
  • 5 Year Percentage Change in Revenue Productivity (US$ CER)
  • 1 Year Percentage Change in Revenue Productivity (US$ CER)

Shareholders Equity

  • Absolute Shareholders Equity (US$ millions YER)
  • Absolute Shareholders Equity (US$ millions CER)
  • 1 Year Absolute Change in Shareholders Equity (US$ millions CER)
  • 5 Year Absolute Change in Shareholders Equity (US$ millions CER)

Investment Rates

  • Percentage Investment Rate against Tangible Assets
  • Percentage Investment Rate against Total Assets

Current Ratios

  • Absolute Current Ratios
  • 5 Year Absolute Change in Current Ratios
  • 1 Year Absolute Change in Current Ratios
  • Gearing %

Part 2

Company Results

  • Abbott Laboratories
  • Abraxis Bioscience
  • Affymax
  • Ajinomoto
  • Alcon Laboratories
  • Alexion Pharmaceuticals
  • Alkermes
  • Allergan
  • Allos Therapeutics
  • Alnylam Pharmaceuticals
  • American Oriental Bioengineering
  • Amgen
  • Amicus Therapeutics
  • Amylin Pharmaceuticals
  • Angiotech
  • Arena Pharmaceuticals
  • Asahi Kasei
  • Astellas
  • Astra Zeneca
  • Axcan Pharma
  • Baxter International
  • Bayer
  • Biogen Idec
  • Biomarin Pharmaceuticals
  • Biotest
  • Biovail
  • Boehringer Ingleheim
  • Bristol-Myers Squibb
  • BTG International
  • Cadence Pharmaceuticals
  • Cangene
  • Caraco Pharmaceutical Laboratories
  • Celgene
  • Cephalon
  • Cerus
  • Chugai
  • Columbia Laboratories
  • Crucell
  • CSL Limited
  • Cubist Pharmaceuticals
  • Cypress Bioscience
  • Cytokinetics
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Dendreon
  • Discovery Laboratories
  • Dr Reddys
  • Durect
  • Dyax
  • Egis
  • Eisai
  • Elan
  • Eli Lilly
  • Emergent Biosolution
  • Endo Pharmaceuticals
  • Enzon Pharmaceuticals
  • Eurand
  • Evotek
  • Exelixis
  • Forest Laboratories
  • Gedeon Richter
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Hospira
  • GTx
  • Human Genome Sciences
  • Idenix
  • Idera
  • Incyte
  • Immunogen
  • Inspire Pharmaceuticals
  • Intermune
  • Ipsen
  • Isis Pharmaceuticals
  • Johnson and Johnson
  • King Pharmaceuticals
  • Kissei Pharmaceutical
  • KRKA
  • Kyowa Hakko Kirin
  • Lexicon Pharmaceuticals
  • Ligand Pharmaceuticals
  • Lundbeck
  • Mannkind
  • MAP Pharmaceuticals
  • Martek Biosciences
  • Medicis Pharmaceutical
  • Merck & Co
  • Merck KGaA
  • Micromet
  • Mitsubishi Tanabe Pharma
  • Molecular Insight
  • Momenta
  • Nabi Biopharmaceuticals
  • Nektar Therapeutics
  • Neurocrine Biosciences
  • Nippon Shinyaku
  • Nipro
  • Novartis
  • Novo Nordisk
  • NPS Pharmaceuticals
  • Nycomed
  • Ono Pharmaceuticals
  • Onyx Pharmaceuticals
  • Optimer Pharmaceuticals
  • Orexigen Therapeutics
  • Orion
  • OSI Pharmaceuticals
  • Osiris Therapeutics
  • Otsuka
  • Pain Therapeutics
  • Paladin Labs
  • Palatin Technologies
  • Par Pharmaceutical Companies
  • Pfizer
  • Pharmasset
  • Pharmaxis
  • Poniard Pharmaceuticals
  • Procter and Gamble
  • Progenics
  • QLT
  • Questcor
  • Ranbaxy
  • Recordati
  • Regeneron
  • Repligen
  • Rigel Pharmaceuticals
  • Roche
  • Salix Pharmaceuticals
  • sanofi-aventis
  • Santen Pharmaceutical
  • Savient Pharmaceuticals
  • Sawai
  • Sciclone
  • Seattle Genetics
  • Seikagaku
  • Shionogi
  • Shire Pharmaceuticals
  • Simcere Pharmaceutical
  • Stada Arzneimittel
  • Sucampo Pharmaceuticals
  • Sumitomo Chemical
  • Supergen
  • Taisho Pharmaceutical
  • Takeda Chemical Industries
  • Teijin
  • Teva Pharmaceutical Industries
  • The Medicines Company
  • Theravance
  • Trimeris
  • UCB
  • United Therapeutics
  • Valeant Pharmaceuticals
  • Vectura
  • Vertex Pharmaceuticals
  • ViroPharma
  • Vivus
  • Warner Chilcott
  • Watson Pharmaceuticals
  • XenoPort
  • Xoma
  • ZymoGenetics

METHODOLOGY

  • Absolute Ranking
  • Absolute Change
  • Percentage Change
  • Currencies
    • Dollar Exchange Rates 2005 - 2009
    • Dollar Index Rates 2005 - 2009
  • Accounting Measures
Back to Top